<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147288</url>
  </required_header>
  <id_info>
    <org_study_id>HIC# 1010007535</org_study_id>
    <nct_id>NCT02147288</nct_id>
  </id_info>
  <brief_title>Prevention of Seroma Formation and Wound Complications Using NPWT Devices</brief_title>
  <official_title>Prevention of Seroma Formation and Wound Complications Using NPWT Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this study is to improve post-operative wound care in the morbidly-obese&#xD;
      body-contouring patient population following massive weight loss undergoing either&#xD;
      panniculectomy or formal abdominoplasty, those patients undergoing complex abdominal wall&#xD;
      reconstruction (i.e. ventral hernia repair) and breast reconstruction with acellular dermal&#xD;
      matrix, as well as patients undergoing regular lipo-abdominoplasty by comparing the&#xD;
      effectiveness of standard closed-suction drains versus the immediate application of&#xD;
      continuous negative pressure via a NPWT (negative pressure wound therapy) device attached to&#xD;
      non-compressible drains. Additionally, we aim to demonstrate increases both in&#xD;
      cost-effectiveness and quality of life in these patients with the use of the NPWT wound care&#xD;
      apparatus.&#xD;
&#xD;
      Hypothesis 1 Continuous negative pressure devices decrease the incidence of wound&#xD;
      complications in comparison with conventional closed suction drains when used in patients&#xD;
      after massive weight loss undergoing body-contouring procedures (panniculectomies alone and&#xD;
      formal abdominoplasties), and in patients undergoing VHR and breast reconstruction with&#xD;
      acellular dermal matrix, as well as those undergoing regular lipo-abdominoplasty.&#xD;
&#xD;
      Hypothesis 2 Although initially more costly than traditional closed suction drains, the use&#xD;
      of continuous negative pressure devices will in the long-term result in lower total health&#xD;
      care costs in the above-stated patient population due to a decreased need for additional&#xD;
      procedures and/or clinical management, including surgical interventions, hospital admissions,&#xD;
      administration of antibiotics, multiple follow-up office visits, and chronic wound care.&#xD;
&#xD;
      Hypothesis 3 Better quality of life is associated with the use of continuous negative&#xD;
      pressure devices compared to closed suction drains in these patient populations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In collaboration with the Yale Bariatric Surgery Program and General Surgery Department,&#xD;
      patients will be identified as 18-years-of-age or older seeking body-contouring procedures&#xD;
      (including panniculectomy and abdominoplasty) following massive weight loss or those patients&#xD;
      in need of complex abdominal wall reconstruction (i.e. ventral hernia repair) and breast&#xD;
      reconstruction necessitating the use of acellular dermal matrix. For the timeframe outlined&#xD;
      in this protocol, the Section of Plastic Surgery at Yale performs surgeries in excess of the&#xD;
      required numbers needed for this study, ensuring timely completion.&#xD;
&#xD;
      Exclusion criteria will include the FDA-identified contraindications to use of continuous&#xD;
      negative pressure suction devices, as follows:&#xD;
&#xD;
        -  presence of necrotic tissue&#xD;
&#xD;
        -  untreated osteomyelitis&#xD;
&#xD;
        -  malignancy (except terminal patients for quality of life issues)&#xD;
&#xD;
        -  untreated malnutrition&#xD;
&#xD;
        -  use on exposed arteries, veins, or organs&#xD;
&#xD;
        -  use on non-enteric and unexplored fistulas Special precaution will be taken when using&#xD;
           the NPWT device in patients on anticoagulants, exhibiting otherwise difficult&#xD;
           hemostasis, or non-adherent patients.&#xD;
&#xD;
      Following a detailed explanation of the study design as well as the associated risks and&#xD;
      benefits that may be incurred by each potential test group, patients who agree to participate&#xD;
      in the study (via informed consent) will be categorized by characteristics including past&#xD;
      medical history, past surgical history, social history, pre- and post-bariatric surgery total&#xD;
      weight loss and BMI and will be randomized into either the control (standard closed suction&#xD;
      drains) or experimental (continuous negative pressure via NPWT device) arm of each group,&#xD;
      depending on the procedure to be performed, as follows:&#xD;
&#xD;
        1. 30 total patients undergoing panniculectomy alone following massive weight loss&#xD;
&#xD;
        2. 30 total patients undergoing formal abdominoplasty (including undermining of skin flaps,&#xD;
           rectus fascia plication and liposuction) following massive weight loss&#xD;
&#xD;
        3. 30 total non-massive weight loss patients undergoing formal lipo-abdominoplasty&#xD;
&#xD;
        4. 30 total patients undergoing ventral hernia repair using acellular dermal matrix&#xD;
&#xD;
        5. 30 total patients undergoing bilateral breast reconstruction using acellular dermal&#xD;
           matrix with 30 breasts randomized to conventional closed suction (one breast left vs&#xD;
           right) and 30 breasts randomized to continuous negative pressure devices (=60 breasts&#xD;
           total)&#xD;
&#xD;
      The control subject arm of each procedure group will be outfitted with 2 standard closed&#xD;
      suction Jackson-Pratt (JP) drains for a period of 4 weeks (unless otherwise specified by the&#xD;
      principle investigator at the point of follow-up), both as an inpatient and at home. The&#xD;
      experimental subject arm of each procedure group will be outfitted with 2 non-compressible&#xD;
      Blake drains attached to continuous suction via NPWT device for a period of 4 weeks (unless&#xD;
      otherwise specified by the principle investigator at the point of follow-up), both as an&#xD;
      inpatient and at home.&#xD;
&#xD;
      In the breast reconstruction group there will be an internal control via the 30 breasts&#xD;
      drained conventionally in the same patient.&#xD;
&#xD;
      To achieve better control of variables, the total length of the incision and area of skin-&#xD;
      undermining along the midline will also be measured and documented in the massive weight loss&#xD;
      patient group to:&#xD;
&#xD;
        1. exactly distinguish the formal abdominoplasty from the panniculectomy patients and&#xD;
&#xD;
        2. evaluate to what extent skin-undermining is a contributing factor to seroma-formation&#xD;
           compared to the patients' intrinsic factors.&#xD;
&#xD;
      All patients from group 1 will be wearing compression girdles starting post-operative day #1;&#xD;
      patients from groups 2 and 3 will start wearing the compression girdles post-operative day #7&#xD;
      (to minimize the risk of central skin flap necrosis); and patients in group 4 will start&#xD;
      wearing a regular abdominal binder on post-operative day #1.&#xD;
&#xD;
      The amount of tumescent solution as well as the amount of lipo-aspirate will be recorded in&#xD;
      each patient in groups 2 &amp; 3.&#xD;
&#xD;
      The following chart will be provided for follow-up lab studies and clinic visits:&#xD;
&#xD;
      Wound-Healing Research Study Schedule and Logistics&#xD;
&#xD;
      Post-Op Follow-up Activities *Duration Week 1 Formal Outpatient Clinic Visit 30 minutes&#xD;
      Follow-Up Blood Labs #1 15 minutes Quality of Life Survey #1 30 minutes&#xD;
&#xD;
      Week 2 Formal Outpatient Clinic Visit 30 minutes Follow-up Blood Labs #2 15 minutes&#xD;
      Ultrasound Examination #1 15-30 minutes&#xD;
&#xD;
      Week 3 Ultrasound Examination #2 15-30 minutes (No formal clinic visit)&#xD;
&#xD;
      Week 4 Formal Outpatient Clinic Visit 30 minutes Quality of Life Survey #4 30 minutes&#xD;
&#xD;
      Week 8 Formal Outpatient Clinic Visit 30 minutes&#xD;
&#xD;
      *All visit duration times are approximate.&#xD;
&#xD;
      Per routine post-operative protocols, patients will be seen in clinic at week 1, 2, 4, and 8,&#xD;
      and as needed clinically. Ultrasounds will be performed for research purposes only at the 2nd&#xD;
      and 4th week visits, and diagnostically in the event that complications arise at any other&#xD;
      point during the post-operative period. QALY surveys will be performed at the 1st and 4th&#xD;
      week post-operative clinic visits.&#xD;
&#xD;
      Together with standard pre-operative blood work, (i.e., complete blood count (CBC), basic&#xD;
      electrolyte panel, International Normalized Ratio (INR)/prothrombin time test (PT)/partial&#xD;
      thromboplastin test (PTT)), we will also obtain albumin, pre-albumin and total protein levels&#xD;
      in each patient on post operative days (PODs) #7 and #14.&#xD;
&#xD;
      Outcomes will be measured as follows:&#xD;
&#xD;
        -  Total amount of fluid drainage comparing the two systems at 1, 2, 4, and 8 weeks (as&#xD;
           long as drains remain in place)&#xD;
&#xD;
        -  Analysis of complication rates including the incidence of infection requiring&#xD;
           antibiotics, wound dehiscence, and the need for seroma drainage and/or surgical&#xD;
           revision.&#xD;
&#xD;
        -  Quantification of seroma formation by ultrasound examination of 5 regions of the&#xD;
           abdominal wall: epigastrium (EPI), umbilical (UMB), hypogastrium (HYPO), right iliac&#xD;
           fossa (RIF) and left iliac fossa (LIF)], at two postoperative periods: (P1), between&#xD;
           postoperative days #11 and #14, and (P2), between postoperative days #18 and #21 as&#xD;
           described by DiMartino et al [20], as well as ultrasound of the superior, medial,&#xD;
           lateral and inferior portions of the reconstructed breasts.&#xD;
&#xD;
      Subjects included in the control (standard closed suction drains) and experimental arms (NPWT&#xD;
      device) of each procedure group will not experience risks to subject privacy, discomforts, or&#xD;
      inconveniences associated with participating in this research project that they would not&#xD;
      otherwise experience with the use of standard closed suction drains currently being used for&#xD;
      post-operative wound care. These standard risks, discomforts, and inconveniences include the&#xD;
      potential for bleeding from drain site, infection at drain site, requirement of changing&#xD;
      collection vessel when full, and pain. The post-operative ultrasound evaluation is also&#xD;
      non-invasive. It is an evaluation which is often performed on patients in the post-operative&#xD;
      period to assess for subcutaneous fluid collections.&#xD;
&#xD;
      The cost-effectiveness of each approach to post-surgical drain placement and design will be&#xD;
      assessed via tracking patient health care costs associated with the specific surgical&#xD;
      procedure performed, the costs associated with immediate post-surgical care, and any&#xD;
      follow-up care incurred during the prolonged post-operative period as designated in the study&#xD;
      design. The relevant costs will be compared between the control and experimental groups of&#xD;
      each arm of the study and the cost-effectiveness ratio will be calculated using an objective,&#xD;
      validated quality of life assessment.&#xD;
&#xD;
      Quality of life will be assessed via an incremental cost-effectiveness ratio, namely the&#xD;
      repeatedly validated quality adjusted life year (QALY) metric achieved through patient&#xD;
      surveys/interviews. The dynamic health assessment survey (DYNHA SF-36) will be used to&#xD;
      evaluate patient health outcomes.&#xD;
&#xD;
      The DYNHA SF-36 Health Survey is a computerized adaptive testing (CAT) version of the&#xD;
      industry standard, fixed-length Short Form Health Survey (SF-36) that has been translated and&#xD;
      made available for use in many country and language-based cohorts [21]. The SF-36 focuses on&#xD;
      assessing functional health and well-being, measuring eight health domains, including&#xD;
      physical functioning, bodily pain, the ability to engage in work and leisure activities,&#xD;
      psychological distress, vitality, and emotional health in order to accurately evaluate an&#xD;
      individual's physical and mental status throughout the recovery period. The advantages of a&#xD;
      dynamic health assessment include brevity without sacrificing accuracy, a focus on parameters&#xD;
      affected by chronic health conditions, reliable outcomes for monitoring individuals, lower&#xD;
      data collection costs, and real-time results with built-in interpretation and scoring.&#xD;
&#xD;
      Regarding the breast reconstruction group, we do not feel that by employing two different&#xD;
      techniques (i.e. continuous vs intermittent/ bulb suction) in the same patient this would&#xD;
      lead to a psychological burden for the patient. We expect that the main outcome difference in&#xD;
      this group will be regarding the ease and comfort with the continuous suction device over the&#xD;
      standard bulb suction. While the patients will likely prefer one over the other device, this&#xD;
      should not have tremendous impact on their recovery in general or in how they cope with their&#xD;
      disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Seroma Formation</measure>
    <time_frame>Two weeks following drain removal</time_frame>
    <description>Quantitative assessment of fluid collection in pre-defined anatomic regions will be performed via ultrasound examination approximately two weeks following removal of drains (either JP or NPWT-associated)</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Seroma</condition>
  <condition>Wound Dehiscence</condition>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>Breast Recon with acellular dermal matrix (ADM) on NPWT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipoabdominoplasty on NPWT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Smith&amp;Nephew Renasys*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominoplasty on NPWT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Smith&amp;Nephew Renasys*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventral Hernia Repair (VHR) on NPWT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Smith&amp;Nephew Renasys*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panniculectomy on NPWT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Smith&amp;Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast Recon with ADM on Jackson-Pratt (JP) Drains</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominoplasty on JP Drains</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipoabdominoplasty on JP Drains</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventral Hernia Repair (VHR) on JP Drains</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panniculectomy on JP Drains</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renasys*GO Negative Pressure Wound Therapy System</intervention_name>
    <description>Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).</description>
    <arm_group_label>Abdominoplasty on NPWT</arm_group_label>
    <arm_group_label>Breast Recon with acellular dermal matrix (ADM) on NPWT</arm_group_label>
    <arm_group_label>Lipoabdominoplasty on NPWT</arm_group_label>
    <arm_group_label>Panniculectomy on NPWT</arm_group_label>
    <arm_group_label>Ventral Hernia Repair (VHR) on NPWT</arm_group_label>
    <other_name>Smith &amp; Nephew, Inc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  30 total patients undergoing panniculectomy alone following massive weight loss&#xD;
&#xD;
          -  30 total patients undergoing formal abdominoplasty (including undermining of skin&#xD;
             flaps, rectus fascia plication and liposuction) following massive weight loss&#xD;
&#xD;
          -  30 total non-massive weight loss patients undergoing formal lipo-abdominoplasty&#xD;
&#xD;
          -  30 total patients undergoing ventral hernia repair using acellular dermal matrix&#xD;
&#xD;
          -  30 total patients undergoing bilateral breast reconstruction using acellular dermal&#xD;
             matrix with 30 breasts randomized to conventional closed suction (one breast left vs&#xD;
             right) and 30 breasts randomized to continuous negative pressure devices (=60 breasts&#xD;
             total)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of necrotic tissue&#xD;
&#xD;
          -  untreated osteomyelitis&#xD;
&#xD;
          -  malignancy (except terminal patients for quality of life issues)&#xD;
&#xD;
          -  untreated malnutrition&#xD;
&#xD;
          -  use on exposed arteries, veins, or organs&#xD;
&#xD;
          -  use on non-enteric and unexplored fistulas Special precaution will be taken when using&#xD;
             the NPWT device in patients on anticoagulants, exhibiting otherwise difficult&#xD;
             hemostasis, or non-adherent patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J G Thomson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <results_first_submitted>August 11, 2016</results_first_submitted>
  <results_first_submitted_qc>December 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2017</results_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Seroma</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited for the &quot;panniculectomy on negative pressure wound therapy (NPWT)&quot; and &quot;panniculectomy on Jackson-Pratt (JP) drains&quot; groups. Patients were not recruited for the remaining arm;s the manufacturer, Smith &amp; Nephew, temporarily halted on the distribution of the device (Renasys*GO negative pressure wound management system).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Panniculectomy on Jackson Pratt (JP) Drains</title>
          <description>Standard of Care</description>
        </group>
        <group group_id="P2">
          <title>Panniculectomy on Negative Pressure Wound Therapy (NPWT)</title>
          <description>The Smith&amp;Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.&#xD;
Renasys*GO Negative Pressure Wound Therapy System: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).</description>
        </group>
        <group group_id="P3">
          <title>Breast Recon With Acellular Dermal Matrix (ADM) on NPWT</title>
        </group>
        <group group_id="P4">
          <title>Breast Recon With ADM on Jackson-Pratt (JP) Drains</title>
        </group>
        <group group_id="P5">
          <title>Lipoabdominoplasty on NPWT</title>
        </group>
        <group group_id="P6">
          <title>Lipoabdominoplasty on JP Drains</title>
        </group>
        <group group_id="P7">
          <title>Abdominoplasty on NPWT</title>
        </group>
        <group group_id="P8">
          <title>Abdominoplasty on JP Drains</title>
        </group>
        <group group_id="P9">
          <title>Ventral Hernia Repair (VHR) on NPWT</title>
        </group>
        <group group_id="P10">
          <title>Ventral Hernia Repair (VHR) on JP Drains</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>post-operative hematoma</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>complications from concurrent hernia rep</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panniculectomy on JP Drains</title>
          <description>Standard of Care</description>
        </group>
        <group group_id="B2">
          <title>Panniculectomy on NPWT</title>
          <description>The Smith&amp;Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.&#xD;
Renasys*GO Negative Pressure Wound Therapy System: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="24" upper_limit="58"/>
                    <measurement group_id="B2" value="46" lower_limit="26" upper_limit="65"/>
                    <measurement group_id="B3" value="43.6" lower_limit="24" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>diabetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-diabetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior abdominal surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" lower_limit="23.1" upper_limit="49.1"/>
                    <measurement group_id="B2" value="30.4" lower_limit="25.1" upper_limit="42.0"/>
                    <measurement group_id="B3" value="31.32" lower_limit="23.1" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-operative prealbumin</title>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" lower_limit="8.9" upper_limit="34.6"/>
                    <measurement group_id="B2" value="21.4" lower_limit="10.3" upper_limit="25.2"/>
                    <measurement group_id="B3" value="20.9" lower_limit="8.9" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incision length</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" lower_limit="26.0" upper_limit="96.0"/>
                    <measurement group_id="B2" value="56.6" lower_limit="26.0" upper_limit="78.5"/>
                    <measurement group_id="B3" value="54.5" lower_limit="26.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Specimen weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.07" lower_limit="0.74" upper_limit="8.52"/>
                    <measurement group_id="B2" value="2.61" lower_limit="0.66" upper_limit="5.50"/>
                    <measurement group_id="B3" value="2.83" lower_limit="0.66" upper_limit="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drain duration</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="8.0" upper_limit="25.0"/>
                    <measurement group_id="B2" value="14" lower_limit="9.0" upper_limit="27.0"/>
                    <measurement group_id="B3" value="15" lower_limit="8.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Seroma Formation</title>
        <description>Quantitative assessment of fluid collection in pre-defined anatomic regions will be performed via ultrasound examination approximately two weeks following removal of drains (either JP or NPWT-associated)</description>
        <time_frame>Two weeks following drain removal</time_frame>
        <population>Among 21 completers (standard of care group); one outlier was excluded from the analysis; 20 subjects were analyzed. Among 22 completers (experimental group), one outlier and 1 who did not have an ultrasound (i.e., fluid was not measured) were excluded, leaving 20 subjects for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panniculectomy on JP Drains</title>
            <description>Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>Panniculectomy on NPWT</title>
            <description>The Smith&amp;Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.&#xD;
Renasys*GO Negative Pressure Wound Therapy System: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Seroma Formation</title>
          <description>Quantitative assessment of fluid collection in pre-defined anatomic regions will be performed via ultrasound examination approximately two weeks following removal of drains (either JP or NPWT-associated)</description>
          <population>Among 21 completers (standard of care group); one outlier was excluded from the analysis; 20 subjects were analyzed. Among 22 completers (experimental group), one outlier and 1 who did not have an ultrasound (i.e., fluid was not measured) were excluded, leaving 20 subjects for analysis.</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="0" upper_limit="132"/>
                    <measurement group_id="O2" value="10.1" lower_limit="0" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Panniculectomy on JP Drains</title>
          <description>Standard of Care</description>
        </group>
        <group group_id="E2">
          <title>Panniculectomy on NPWT</title>
          <description>The Smith&amp;Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.&#xD;
Renasys*GO Negative Pressure Wound Therapy System: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>post-operative hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>abcess with infected mesh</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>seroma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>wound dehiscence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>stitch absess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marc Walker</name_or_title>
      <organization>Yale University</organization>
      <email>marc.walker@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

